Published on February 10, 2010 at 1:02 AM
Ikonisys announced today that they will exhibit their proprietary oncoFISH®
cervical test at the Eurogin 2010 Cervical Cancer Prevention Conference
held at the Grimaldi Forum in Monte Carlo from February 17-20.
oncoFISH
cervical is a companion test designed to work in conjunction with
currently used cervical cancer screening tests like the Pap smear and
HPV tests prior to colposcopy. oncoFISH cervical serves as an
additional aid for medical professionals to better manage cervical
dysplasia.
Currently offered in the United States as a laboratory developed test,
Ikonisys will now launch this test to the broader European market as a
CE marked product. Centro
Diagnostico Italiano (CDI), a full service outpatient health
facility, was the first in Europe to offer oncoFISH cervical out
of their laboratory. “The objective presence of cells with a significant
amplification of 3q26 is the smoking gun in the pathogenesis of cervical
cancer: finally we can give our gynecologists a clearer picture. The oncoFISH
cervical test enables us to offer a new dimension of cervical cancer
diagnosis and we are thrilled to be the first in Europe to offer such a
test,” said Vittorio Grazioli, MD. Located in Milan, CDI averages over
3.7 million diagnostic tests per year.
Based on enumerating fluorescence markers in the 3q region, the oncoFISH
cervical test will be sold as an application for the Ikoniscope® Digital
Microscopy System. The Ikoniscope and oncoFISH cervical probe
kits will be sold directly to customers throughout Europe.
In addition to the conference, Ikonisys will be holding a workshop to
further demonstrate and explain the clinical value of this test.
SOURCE Ikonisys